Osteoporosis is characterized by low bone density, micro-architectural 
Introduction
Osteoporosis is the one of the most common bone disease & a ects millions of people worldwide. It is de ned as low bone density with micro architectural deterioration of bone tissue leading to enhanced bone fragility & increased fracture risk. Osteoporosis is often asymptomatic for many years until the end-organ complications (fractures) occur.
ese fractures and their consequences, which include pain, disability, deformity, and sometimes premature death, are recognized clinical sequelae of osteoporosis. Normally in adults resorbed bone is replaced by an equal amount of new bone tissue. us the mass of skeleton remains constant after peak bone mass is achieved in childhood. After 40 years however the resorption and formation process become
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Patwary MI 1 , Bari MZJ 2 , Isha IT 3 imbalanced and resorption exceeds formation. Excessive bone loss is due to an increase in osteoclastic activity or as decrease in osteoblastic activity.
e prevalence of osteoporosis increases with age, re ecting the fact that bone density declines with age, especially in women. Chronic diseases that increase the risk of falling or frailty including dementia Parkinson's disease and multiple sclerosis also increase fracture risk. Osteoporotic bone is more likely to fracture than normal bone at any level of trauma and a fracture in a person over 50 should trigger evaluation for osteoporosis. is often does not occur because post fracture care is not always well coordinated. Fractures are themselves also risk factors for future fractures. Vertebral fractures increase the risk of other vertebral fractures as well as fractures of the peripheral skeleton such as the hip and wrist. Wrist fractures also increase the risk of vertebral and hip fractures. e risk for subsequent fractures is particularly high in the rst several years after the rst fracture and the risk wanes considerably thereafter. Consequently among individuals over age 50 any fracture should be considered as potentially related to osteoporosis regardless of the circumstances of the fracture. [1] [2] [3] [4] Epidemiology Bone mass is a major determinant of fracture risk. For every 10% decline in bone mass, there is an approximate doubling of fracture risk in the population. Fractures related to osteoporosis are estimated to a ect around 30% of women and 12% of men in developed countries, and are a major public health problem. In the UK alone, fractures are sustained by over 250 000 individuals annually, with treatment costs of about £1.75 billion. In the United States and Europe, osteoporosis-related fractures are more common among women than men, presumably due to a lower peak bone mass as well as postmenopausl bone loss in women. However this sex di erence in bone density and age-related increase in hip fractures is not as apparent in some other cultures possibly due to genetics, physical activity level, or diet. In the United States, as many as 9 million adults have osteoporosis (T-score <-2.5 in either spine or hip) and an additional 48 million individuals have bone mass levels that put them at increased risk of developing osteoporosis (e.g., bone mass T score <-1.0).
ere are about 550 000 vertebral crush fractures, 400,000 wrist fractures and 135000 pelvic fractures per year in the United States which currently costing a total of about s 15 billion annually. Only a fraction (estimated to be one-third) of them are recognized clinically because many are relatively asymptomatic and are identi ed incidentally during radiography for other purposes. Vertebral fractures rarely require hospitalization but are associated with long-term morbidity and a slight increase in mortality rates, primarily related to pulmonary disease. e probability that a 50-year-old white individual will have a hip fracture during his or her lifetime is 14% for women and 5% for men; the risk for African Americans is lower and the risk for Asians is roughly equal to that for whites. [1] [2] [3] [4] 
Pathophysiology
Normally function of osteoclast is bone resorption and osteoblast is osteoid formation &mineralization. After the age of 40 yrs bone resorption is more than formation i.e. increase in osteoclastic activity and/or decrease in osteoblastic activity. If osteoclast penetrate In trabecular bone they leave no template for new bone formation causing rapid bone loss. In cortical bone it causes activation of remodeling and ultimately more porous bone is formed. In women there is an accelerated phase of bone loss after the menopause due to oestrogen de ciency, which causes uncoupling of bone resorption and bone formation, such that the amount of bone removed by osteoclasts exceeds the rate of new bone formation by osteoblasts. Age-related bone loss is a distinct process that accounts for the gradual bone loss that occurs with advancing age in both genders. Bone resorption is not particularly increased but bone formation is reduced and fails to keep pace with bone resorption. 1, 2 Peak bone mass and bone loss are regulated by both genetic and environmental factor, Polymorphisms have been identi ed in several genes that contribute to the pathogenesis of osteoporosis and many of these are in the RANKL (Receptor activator of nuclear factor kappa-B ligand) and Wnt signalling pathways, which play a critical role in regulating bone turnover. Environmental factors, such as exercise and calcium intake during growth and adolescence, are important in maximizing peak bone mass and in regulating rates of post-menopausal bone loss. Smoking has a detrimental e ect on bone mineral density (BMD) and is associated with an increased fracture risk, partly because female smokers have an earlier menopause than non-smokers. Heavy alcohol intake is a recognized cause of osteoporosis and fractures, but moderate intake does not substantially alter risk. e most common causes of male osteoporosis are hypogonadism, corticosteroid use and alcoholism and smoking. A important cause of osteoporosis in both sexes is corticosteroid. Although there is no 'safe' dose of corticosteroid, the risk increases when the dose of prednisolone exceeds 7.5 mg daily and is continued for more than 3 months. 1-4 ( Figure-1 
Figure 2: Micrographs of Normal vs Osteoporotic Bone

Classi cation of osteoporosis 2-3
Osteoporosis may be primary or secondary. Primary osteoporosis may be postmenopausal (Type I) caused by lack of estrogen, which causes uncoupling of resorption and bone formation, such that the amount of bone removed by osteoclasts exceeds the rate of new bone formation by osteoblasts. Primary osteoporosis may also be age-associated (Type II) where bone resorption is not particularly increased but bone formation is reduced and fails to keep pace with bone resorption. 
FRAX Tool
e World Health Organization (WHO) has developed a freely available, computer-based fracture risk assessment tool, FRAX that can be used with or without BMD, to estimate the 10-year probability of hip fracture and major osteoporotic fracture (hip, clinical spine, proximal humerus, forearm) in untreated men and women between the ages of 40 and 90. 6 Table- Exposure to medications known to have harmful skeletal e ects (e.g., glucocorticoids, aromatase inhibitors, androgen-deprivation therapy, and anticonvulsants) should be minimized or avoided.
For frail, elderly patients, the importance of fall prevention by means including modifying the home environment; leg-strengthening exercises; balance training; and avoiding drugs that may cause sedation, hypotension, or dizziness should be emphasize.
Treatment goal is to prevent fractures and skeletal deformity, increasing or stabilize or bone mass, relieving symptoms of fractures and maximize physical function.
Who should be treated [1] [2] [3] [4] Postmenopausal women and men age ≥ 50 presenting with:
A hip or vertebral fracture T-score < -2.5 at femoral neck, total hip or spine and secondary causes with high risk factors.
Other prior fractures &T between -1.0 and -2.5 at femoral neck, total hip, or spine Low BMD T-between -1.0 and -2.5 at the femoral neck, total hip, or spine and 10-yr probability of hip fracture ≥3% or a 10-yr probability of any major osteoporosis related fracture ≥ 20%
Bisphosphonate: Bisphosphonates inhibit bone resorption by binding to hydroxyapatite crystals on the bone surface. When osteoclasts attempt to resorb bone that contains bisphosphonate, the drug is released within the cell, where it inhibits key signaling pathways that are essential for osteoclast function. [1] [2] [3] [4] Alendronate : It reduces risk of vertebral fractures by 40% and non-vertebral fractures by about 25% in postmenopausal women with osteoporosis. [1] [2] [3] [7] [8] [9] [10] Dose-For prevention (5 mg daily and 35 mg weekly) -For treatment (10 mg daily and 70 mg weekly) 1-3,7-10 
Ibandronate is sometimes used but the evidence for prevention of non-vertebral fractures is less robust. Reduces the incidence of spine fracture by about 50% over 3 years. [1] [2] [3] [11] [12] Risedronate: Approved for prevention and treatment of postmenopausal, male and Glucocorticoid induced osteoporosis. Reduces incidence of spine fracture by 41-49% & non-spine fracture by 36% over 3 years with a prior spine fracture. 1-3, 13-14 Dose -5 mg daily, -35 mg weekly [1] [2] [3] [13] [14] Zoledronate: Zoledronic acid is e ective in the treatment of post-menopausal osteoporosis, corticosteroid-induced osteoporosis and osteoporosis in men. It is especially useful for secondary prevention of fractures in elderly patients with hip fracture and reduces mortality in this group, being the only treatment that has been shown to modify this. It reduces incidence of spine fracture by 75%, hip fracture by 41%, and non-vertebral fracture by 25% over 3 years. [1] [2] [3] [15] [16] Dose-5 mg by intravenous infusion once yearly [1] [2] [3] [15] [16] Adverse e ects of Bisphosphonates 1
Common
• Upper gastrointestinal intolerance (oral)
• Acute phase response (intravenous)
Less common
• Atrial brillation (intravenous zoledronic acid)
• Renal impairment (intravenous zoledronic acid)
• Atypical subtrochanteric fractures No longer considered as rst line therapy [1] [2] 18 Raloxifene: It results in a modest increase in BMD (2%) and a 40% reduction in vertebral fractures, but does not in uence the risk of non-vertebral fracture and can provoke muscle cramps and worsen hot ushes but reduces the risk of breast cancer. Reduction of hip and other non-vertebral fracture not demonstrated. [1] [2] [3] [19] [20] Calcitonin: Calcitonin is an osteoclast inhibitor that has weak anti fracture e cacy but is no longer used in the treatment of osteoporosis because of concerns about an increased risk of cancer with long-term use. [1] [2] [3] 21 Teriparatide: Teriparatide increases BMD by 10% or more in osteoporotic subjects and reduces risk of vertebral fractures by about 65% and non-vertebral fractures by 50%.It is also e ective in corticosteroid-induced osteoporosis and appears superior to alendronate in terms of BMD gain and vertebral fracture reduction. It is also e ective in male osteoporosis. [1] [2] [3] 22 Strontium ranelate: Strontium ranelate reduces vertebral fracture risk by about 50% after 3 years and non-vertebral fracture risk by 12%. It has a weak inhibitory e ect on bone resorption, stimulates biochemical markers of bone formation and is incorporated within hydroxyapatite crystals in place of calcium. 1 Denosumab: Denosumab is a monoclonal antibody that neutralizes the e ects of RANKL. It is administered by subcutaneous injection every 6 months in the treatment of osteoporosis. It is a powerful inhibitor of bone resorption and reduces the risk of hip fractures by 40%, vertebral fractures by 70% and other non-vertebral fractures by 20%. [1] [2] [3] 23 
Management of Vertebral Fractures 1
Conservative: Oral pain management Physical therapy
Surgical:
Kyphoplasty Vertebroplasty
Evaluating Treatment E cacy
Serial BMD measurements by DEXA can be used to monitor for response to therapy. It is appropriate to measure BMD 12 to 24 months after initiating or changing therapy and periodically thereafter. An increase or stability in BMD is considered an acceptable response to therapy Ensure compliance A signi cant loss of BMD usually represents non-response or a suboptimum response to therapy, suggesting the need for reevaluation of treatment and evaluation for secondary causes of osteoporosis and considered for change in therapy.
Measurement of bone resorption (C-telopeptide [CTX] is the preferred marker) before initiating therapy and 3-6 months after starting therapy provides an earlier estimate of patient response than does bone densitometry .A decline in resorptive markers can be ascertained after treatment with potent antiresorptive agents such as bisphosphonates denosumab or standard-dose estrogen; this e ect is less marked after treatment with weaker agents such as raloxifene or intranasal calcitonin.
Bone resorption markers include urine and serum N-telopeptide, serum Ctelopeptide, urine pyridinoline, and urine deoxypyridinoline, urine hydroxyproline Bone formation markers include serum osteocalcin, serum bone-speci c alkaline phosphatase, and serum procollagen type 1 N terminal propeptide. [1] [2] [3] [25] [26] Stopping erapy e evidence based on duration of treatment is limited. Alendronate and Risedronate appear to be safe and e ective for up to 10 years in most patients, but some randomized trial with alendronate showed that overall fracture rates were similar in those given 5 years. So stopping the drug after 5 years does not signi cantly increase fracture risk but patients with very high fracture risk may bene t from continued therapy. [1] [2] 25 Osteoporosis is the most common bone disease and a ects million of People worldwide. Despite the availability of excellent clinical tools to assess fracture risk and widely available drugs to reduce fracture risk, osteoporosis remains under diagnosed and undertreated. Bones become fragile and often diagnosed after a serious fracture. DEXA scan is the pivotal investigation for diagnosis of osteoporosis. Always secondary causes should be evaluated in diagnosing osteoporosis. It has no cure but preventable and e ectively treatable with non-pharmacological intervention and pharmacological therapy.
